Solus Advanced Materials will advance into the messenger Ribonucleic Acid (mRNA) vaccine raw material market based on its biomaterial technology.
Solus Advanced Materials announced on the 29that it has started independently developing 'structural phospholipids', a key raw material for mRNA vaccine delivery systems. Structural phospholipids make up lipid nanoparticles (LNPs) that serve as drug carriers and are essential for maintaining mRNA vaccine effectiveness.
It plans to diversify vaccine delivery pipeline by increasing the use of structure phospholipids based on its proprietary technology.
Solus Advanced Materials plans to develop and commercialize a domestic vaccine delivery system with superior safety and efficacy by adding SunBio technology, which specializes in biosimilars, to structural phospholipids. SunBio supplies vaccine delivery materials to Pfizer.
The new biomaterials developed by the two companies maximize the drug delivery effect and minimize side effects. Sous explained that the materials are highly likely to be used as a next-generation anticancer drug delivery system for cancer patients and mRNA vaccines.
Yong-jin Choi, Head of Bio Business Division, said “Ourdistinctive technology in developing and accumulating biomaterials for 30 years has allowed us to enter the mRNA vaccine raw material market in a timely manner. Through open innovation, we have turned on a green light for diversifying the bio business portfolio and localizing key raw materials for vaccines.”
By Reporter Ji-woong Kim jw0316@etnews.com